Biotech News

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Vaccinex (VCNX)Vaccinex2026-06-25 13:46 ESTCompany update

Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. ROCHESTER, N.Y. , Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc.

Open original release

Related news

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

VCNXVaccinex2026-06-25 13:46 EST

Vaccinex Reports 2025 Annual Financial Results

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Vaccinex

Vaccinex is an infectious-disease or vaccine company focused on immunity-driven programs where clinical, regulatory, and demand cycles can shift quickly.

Recent company news

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

VCNXVaccinex2026-06-26 00:18 EST

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States